214. Deputy John Brassil asked the Minister for Health the status of the implementation of the HSE’s best-value biologics process; if the HSE has plans to review this process to drive greater adoption of the designated best-value biological drug; if the HSE will expand this programme to further therapy areas in which a biosimilar drug is available here; and if he will make a statement on the matter. [48231/19]

Summary

214. Deputy John Brassil asked the Minister for Health the status of the implementation of the HSE’s best-value biologics process; if the HSE has plans to review this process to drive greater adoption of the designated best-value biological drug; if the HSE will expand this programme to further therapy areas in which a biosimilar drug is available here; and if he will make a statement on the matter. [48231/19]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 20 November 2019

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.